Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4D | Q08499 | 9/20 | 0.36 |
| ▸ | PDE4A | P27815 | 5/20 | 0.36 |
| ▸ | PDE4B | Q07343 | 5/20 | 0.36 |
| ▸ | PDE4C | Q08493 | 5/20 | 0.36 |
| ▸ | RIPK1 | Q13546 | 7/20 | 0.33 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.33 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.33 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.32 |
| ▸ | AKT1 | P31749 | 1/20 | 0.32 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.32 |
| ▸ | MTOR | P42345 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24180090 | 0.87 | RIPK1 (0.41) | PDE4DPDE4APDE4BPDE4CRIPK1 | |
| SCHEMBL16744731 | 0.80 | PDE4D (0.35) | PDE4DPDE4APDE4BPDE4CRIPK1 | |
| SCHEMBL24180071 | 0.79 | RIPK1 (0.39) | PDE4DPDE4APDE4BPDE4CRIPK1 | |
| SCHEMBL23753787 | 0.74 | RIPK1 (0.38) | PDE4DPDE4APDE4BPDE4CRIPK1 | |
| SCHEMBL22389460 | 0.73 | RIPK1 (0.39) | PDE4DPDE4APDE4BPDE4CRIPK1 | |
| SCHEMBL22391505 | 0.73 | RIPK1 (0.39) | PDE4DPDE4APDE4BPDE4CRIPK1 | |
| SCHEMBL22957911 | 0.72 | RIPK1 (0.44) | RIPK1 | |
| SCHEMBL22957901 | 0.72 | RIPK1 (0.44) | RIPK1 | |
| SCHEMBL16747649 | 0.71 | PDE4D (0.38) | PDE4DPDE4APDE4BPDE4CRIPK1 | |
| SCHEMBL16744732 | 0.71 | PDE4D (0.38) | PDE4DPDE4APDE4BPDE4CRIPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9174974-B2 | Macrocyclic factor VIIa inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-11-03 | — | — | US | disclosed |
| US-20150148313-A1 | MACROCYCLIC FACTOR VIIA INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2015-05-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150148313-A1 | MACROCYCLIC FACTOR VIIA INHIBITORS | F7, F12, F5 | PDE4D 2115/4885PDE4A 2184/4885PDE4B 1523/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.